Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement.
The Australian Federal Government has announced funding for the Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Centre (SMART CRC), with Cynata Therapeutics set to play a key role as a Core Partner. This initiative aims to create a collaborative ecosystem for regenerative therapy manufacturing in Australia, with a budget of $238 million and over 60 partners. The involvement in SMART CRC presents Cynata with opportunities to advance its research and development projects, potentially enhancing its position in the regenerative medicine industry.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage company specializing in stem cell and regenerative medicine. It focuses on developing therapies using its proprietary Cymerus™ platform, which leverages induced pluripotent stem cells (iPSCs) for the economic manufacture of cell therapy products at a commercial scale. Cynata has shown positive results in clinical trials for various conditions, including graft versus host disease and diabetic foot ulcers, and is conducting further trials for other diseases.
YTD Price Performance: -27.89%
Average Trading Volume: 1,111
Technical Sentiment Signal: Buy
Current Market Cap: $28.9M
For an in-depth examination of CYP stock, go to TipRanks’ Stock Analysis page.